REGENTIS BIOMATERIALS LTD. (RGNT) — SEC Form D Filing
REGENTIS BIOMATERIALS LTD. (RGNT) filed an SEC Form D on June 25, 2026, reporting $6.50M raised in Medical Devices.
Form D filing details
- Filing
- SEC Form D
- Filing date
- June 25, 2026
- Amount reported
- $6.50M
- Industry
- Medical Devices
- Website
- https://www.regentis.co.il/
What the company does
Securities: Equity. Exemption: Rule 506(c). Incorporated: ISRAEL
Problem
Patients suffer from painful injuries to articular knee cartilage, and there is an unmet need for effective treatments for these cartilage injuries.
Solution
Regentis Biomaterials is developing GelrinC, a cell-free, off-the-shelf degradable hydrogel implant designed to treat painful articular knee cartilage injuries and regenerate damaged tissue.
Verdict
Investors backed this company for its defined focus on treating articular knee cartilage injuries, not for broad regenerative medicine claims. The implicit bet was on GelrinC's ability to navigate clinical trials and regulatory hurdles more efficiently than cell-based therapies, leveraging an off-the-shelf characteristic to streamline surgical procedures. Upside was limited by the specialized application, suggesting a niche market penetration rather than a platform technology that could address multiple tissue types. This cleared because of a clearly scoped clinical pathway, not because of unproven future therapeutic modalities.
Source: SEC EDGAR Form D filing